S&P 500   4,228.48 (-1.29%)
DOW   33,706.74 (-0.86%)
QQQ   322.80 (-1.97%)
AAPL   171.51 (-1.52%)
MSFT   286.10 (-1.40%)
META   167.90 (-3.87%)
GOOGL   117.23 (-2.45%)
AMZN   138.16 (-2.91%)
TSLA   890.00 (-2.05%)
NVDA   178.28 (-5.03%)
NIO   19.08 (-4.17%)
BABA   89.63 (-1.22%)
AMD   95.92 (-4.50%)
T   18.43 (+0.00%)
MU   60.46 (-4.00%)
CGC   3.83 (+0.52%)
F   15.88 (-1.67%)
GE   77.72 (-1.88%)
DIS   120.24 (-1.98%)
AMC   18.23 (-5.50%)
PYPL   96.62 (-3.24%)
PFE   49.25 (+1.38%)
NFLX   241.21 (-1.62%)
S&P 500   4,228.48 (-1.29%)
DOW   33,706.74 (-0.86%)
QQQ   322.80 (-1.97%)
AAPL   171.51 (-1.52%)
MSFT   286.10 (-1.40%)
META   167.90 (-3.87%)
GOOGL   117.23 (-2.45%)
AMZN   138.16 (-2.91%)
TSLA   890.00 (-2.05%)
NVDA   178.28 (-5.03%)
NIO   19.08 (-4.17%)
BABA   89.63 (-1.22%)
AMD   95.92 (-4.50%)
T   18.43 (+0.00%)
MU   60.46 (-4.00%)
CGC   3.83 (+0.52%)
F   15.88 (-1.67%)
GE   77.72 (-1.88%)
DIS   120.24 (-1.98%)
AMC   18.23 (-5.50%)
PYPL   96.62 (-3.24%)
PFE   49.25 (+1.38%)
NFLX   241.21 (-1.62%)
S&P 500   4,228.48 (-1.29%)
DOW   33,706.74 (-0.86%)
QQQ   322.80 (-1.97%)
AAPL   171.51 (-1.52%)
MSFT   286.10 (-1.40%)
META   167.90 (-3.87%)
GOOGL   117.23 (-2.45%)
AMZN   138.16 (-2.91%)
TSLA   890.00 (-2.05%)
NVDA   178.28 (-5.03%)
NIO   19.08 (-4.17%)
BABA   89.63 (-1.22%)
AMD   95.92 (-4.50%)
T   18.43 (+0.00%)
MU   60.46 (-4.00%)
CGC   3.83 (+0.52%)
F   15.88 (-1.67%)
GE   77.72 (-1.88%)
DIS   120.24 (-1.98%)
AMC   18.23 (-5.50%)
PYPL   96.62 (-3.24%)
PFE   49.25 (+1.38%)
NFLX   241.21 (-1.62%)
S&P 500   4,228.48 (-1.29%)
DOW   33,706.74 (-0.86%)
QQQ   322.80 (-1.97%)
AAPL   171.51 (-1.52%)
MSFT   286.10 (-1.40%)
META   167.90 (-3.87%)
GOOGL   117.23 (-2.45%)
AMZN   138.16 (-2.91%)
TSLA   890.00 (-2.05%)
NVDA   178.28 (-5.03%)
NIO   19.08 (-4.17%)
BABA   89.63 (-1.22%)
AMD   95.92 (-4.50%)
T   18.43 (+0.00%)
MU   60.46 (-4.00%)
CGC   3.83 (+0.52%)
F   15.88 (-1.67%)
GE   77.72 (-1.88%)
DIS   120.24 (-1.98%)
AMC   18.23 (-5.50%)
PYPL   96.62 (-3.24%)
PFE   49.25 (+1.38%)
NFLX   241.21 (-1.62%)
NASDAQ:ATNX

Athenex - ATNX Stock Forecast, Price & News

$0.46
-0.04 (-7.55%)
(As of 08/19/2022 03:59 PM ET)
Add
Compare
Today's Range
$0.45
$0.49
50-Day Range
$0.41
$1.11
52-Week Range
$0.41
$3.91
Volume
76,986 shs
Average Volume
3.72 million shs
Market Capitalization
$55.36 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$4.00

Athenex MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.50 Rating Score
Upside/​Downside
768.1% Upside
$4.00 Price Target
Short Interest
Healthy
1.88% of Shares Sold Short
Dividend Strength
N/A
Sustainability
-1.97
Upright™ Environmental Score
News Sentiment
0.55mentions of Athenex in the last 14 days
Based on 3 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($0.64) to ($0.19) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.43 out of 5 stars

Medical Sector

206th out of 1,119 stocks

Pharmaceutical Preparations Industry

88th out of 549 stocks

ATNX stock logo

About Athenex (NASDAQ:ATNX) Stock

Athenex, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of drugs for the treatment of cancer. It operates through three segments: Oncology Innovation Platform, Global Supply Chain Platform, and Commercial Platform. The company's Orascovery product candidates include Oral paclitaxel and encequidar, an oral dosage form, which is in Phase III trial for metastatic breast cancer, as well as various clinical studies in cutaneous angiosarcoma, advanced gastric cancer, and advanced solid malignancies. It also offers Src Kinase product candidates comprising Tirbanibulin ointments for actinic keratosis, skin cancers, and psoriasis. In addition, the company is developing KUR-501, an autologous product that is in a phase I clinical trial for treating children with relapsed-refractory (R/R) high risk neuroblastoma; KUR-502, an allogeneic product, which is in a phase I clinical trial for treating adults with R/R CD19 positive malignancies, including B cell lymphoma, acute lymphoblastic leukemia, and chronic lymphocytic leukemia; and KUR-503, an allogeneic product that is in preclinical development for advanced hepatocellular carcinomas, as well as TCRT-ESO-A2, an autologous T cell receptor (TCR)-T cell therapy that is in phase 1 clinical trial for solid tumors. Further, it is developing dual absorption enhancers to inhibit the P-gp transporter and the cytochrome p450 3A enzymes within the gastrointestinal tract; and has a portfolio of TCRs that recognize hotspot mutations in p53, KRAS, and EGFR genes for multiple tumors. The company was formerly known as Kinex Pharmaceuticals LLC and changed its name to Athenex, Inc. in August 2015. Athenex, Inc. was incorporated in 2003 and is headquartered in Buffalo, New York.

Athenex Stock Down 8.3 %

NASDAQ:ATNX traded down $0.04 on Friday, reaching $0.45. The stock had a trading volume of 68,731 shares, compared to its average volume of 3,721,481. The company has a current ratio of 1.31, a quick ratio of 0.89 and a debt-to-equity ratio of 4.92. Athenex has a 1 year low of $0.41 and a 1 year high of $3.91. The business has a 50 day moving average price of $0.57 and a 200 day moving average price of $0.67. The company has a market capitalization of $54.89 million, a price-to-earnings ratio of -0.26 and a beta of 1.09.

Athenex (NASDAQ:ATNX - Get Rating) last announced its quarterly earnings results on Thursday, July 28th. The company reported ($0.28) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.13) by ($0.15). Athenex had a negative net margin of 160.39% and a negative return on equity of 258.81%. During the same period last year, the business earned ($0.33) EPS. On average, analysts forecast that Athenex will post -0.64 EPS for the current fiscal year.

Receive ATNX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Athenex and its competitors with MarketBeat's FREE daily newsletter.

ATNX Stock News Headlines

Recap: Athenex Q2 Earnings - Benzinga
See More Headlines
Receive ATNX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Athenex and its competitors with MarketBeat's FREE daily newsletter.

ATNX Company Calendar

Last Earnings
7/28/2022
Today
8/19/2022
Next Earnings (Estimated)
11/03/2022
Fiscal Year End
12/31/2022

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:ATNX
Fax
N/A
Employees
652
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$4.00
High Stock Price Forecast
$5.00
Low Stock Price Forecast
$3.00
Forecasted Upside/Downside
+778.7%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.50
Research Coverage
2 Analysts

Profitability

Net Income
$-199,770,000.00
Net Margins
-160.39%
Pretax Margin
-162.95%

Debt

Sales & Book Value

Annual Sales
$120.18 million
Book Value
($0.05) per share

Miscellaneous

Free Float
107,015,000
Market Cap
$55.36 million
Optionable
Optionable
Beta
1.09

Key Executives

  • Dr. Yiu-Nam Lau F.R.C.P. (Age 62)
    M.B.B.S., M.D., Ph.D., Chairman & CEO
    Comp: $547.73k
  • Mr. Jeffrey M. Yordon (Age 73)
    COO & Pres of Athenex Pharmaceutical Division
    Comp: $424.72k
  • Dr. Daniel Lang M.D. (Age 56)
    Pres of Athenex Cell Therapy
    Comp: $333.17k
  • Dr. Allen Barnett
    Co-Founder & Pres Emeritus
  • Mr. Joe Annoni C.F.A.
    Chief Financial Officer
  • Caileigh Dougherty
    Director of Investor Relations
  • Ms. Jacqueline Li
    VP of Alliance Management & Corp. Devel.
  • Mr. John W. Matthei
    VP of HR
  • Dr. David Cutler
    Deputy Chief Medical Officer of Biologics & Cell Therapy
  • Mr. Timothy Cook (Age 60)
    Chief Bus. & Commercial Officer of Proprietary Drugs













ATNX Stock - Frequently Asked Questions

Should I buy or sell Athenex stock right now?

2 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Athenex in the last year. There are currently 1 hold rating and 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "buy" ATNX shares.
View ATNX analyst ratings
or view top-rated stocks.

What is Athenex's stock price forecast for 2022?

2 analysts have issued 12-month price targets for Athenex's shares. Their ATNX share price forecasts range from $3.00 to $5.00. On average, they predict the company's stock price to reach $4.00 in the next year. This suggests a possible upside of 712.3% from the stock's current price.
View analysts price targets for ATNX
or view top-rated stocks among Wall Street analysts.

How have ATNX shares performed in 2022?

Athenex's stock was trading at $1.36 on January 1st, 2022. Since then, ATNX stock has decreased by 63.8% and is now trading at $0.4924.
View the best growth stocks for 2022 here
.

When is Athenex's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, November 3rd 2022.
View our ATNX earnings forecast
.

How were Athenex's earnings last quarter?

Athenex, Inc. (NASDAQ:ATNX) issued its earnings results on Thursday, July, 28th. The company reported ($0.28) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.13) by $0.15. Athenex had a negative trailing twelve-month return on equity of 258.81% and a negative net margin of 160.39%. During the same quarter in the prior year, the firm posted ($0.33) EPS.

What other stocks do shareholders of Athenex own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Athenex investors own include NVIDIA (NVDA), Micron Technology (MU), Advanced Micro Devices (AMD), CRISPR Therapeutics (CRSP), QUALCOMM (QCOM), Amarin (AMRN), AbbVie (ABBV), Gilead Sciences (gild), OPKO Health (OPK) and Sorrento Therapeutics (SRNE).

When did Athenex IPO?

(ATNX) raised $72 million in an IPO on Wednesday, June 14th 2017. The company issued 6,000,000 shares at $11.00-$13.00 per share. Credit Suisse, Deutsche, Bank Securities and J.P. Morgan served as the underwriters for the IPO and ICBC International was co-manager.

What is Athenex's stock symbol?

Athenex trades on the NASDAQ under the ticker symbol "ATNX."

Who are Athenex's major shareholders?

Athenex's stock is owned by a number of institutional and retail investors. Top institutional shareholders include Millennium Management LLC (3.76%), Renaissance Technologies LLC (1.61%), Citadel Advisors LLC (0.48%), State Street Corp (0.24%), Goldman Sachs Group Inc. (0.22%) and Northern Trust Corp (0.11%). Insiders that own company stock include Benson Kwan Hung Tsang, Jinn Wu, Johnson Yiu Nam Lau, Jordan Kanfer, Kim Campbell, Life Sciences Maste Perceptive, Manson Fok, Perceptive Advisors Llc, Randoll Sze, Rudolf Kwan and William Wei Zuo.
View institutional ownership trends
.

How do I buy shares of Athenex?

Shares of ATNX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Athenex's stock price today?

One share of ATNX stock can currently be purchased for approximately $0.49.

How much money does Athenex make?

Athenex (NASDAQ:ATNX) has a market capitalization of $59.88 million and generates $120.18 million in revenue each year. The company earns $-199,770,000.00 in net income (profit) each year or ($1.72) on an earnings per share basis.

How many employees does Athenex have?

The company employs 652 workers across the globe.

How can I contact Athenex?

Athenex's mailing address is 1001 Main Street Suite 600, Buffalo NY, 14203. The official website for the company is www.athenex.com. The company can be reached via phone at (716) 427-2950 or via email at stevenrubis@athenex.com.

This page (NASDAQ:ATNX) was last updated on 8/19/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Privacy Policy | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see Barchart's disclaimer.